MX2019007511A - Moleculas de union para el tratamiento del cancer. - Google Patents

Moleculas de union para el tratamiento del cancer.

Info

Publication number
MX2019007511A
MX2019007511A MX2019007511A MX2019007511A MX2019007511A MX 2019007511 A MX2019007511 A MX 2019007511A MX 2019007511 A MX2019007511 A MX 2019007511A MX 2019007511 A MX2019007511 A MX 2019007511A MX 2019007511 A MX2019007511 A MX 2019007511A
Authority
MX
Mexico
Prior art keywords
cadherin
tnf
cancer
treatment
binding molecules
Prior art date
Application number
MX2019007511A
Other languages
English (en)
Inventor
Voynov Vladimir
Ganesan Rajkumar
SHAABAN Abdulsalam
Kuenkele Klaus-Peter
Eryilmaz Ertan
Fenn Timothy
Manuel Garcia-Martinez Juan
Ho Jason
Koessl Christian
Sen Saurabh
Wernitznig Andreas
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019007511A publication Critical patent/MX2019007511A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a moléculas de unión que se unen específicamente al receptor 2 del ligando inductor de la apoptosis relacionado con TNF (TRAILR2) y a cadherina 17 (CDH17) y su uso medicinal, composiciones farmacéuticas que las comprenden y métodos para usarlas como agentes para el tratamiento y/o la prevención del cáncer.
MX2019007511A 2016-12-22 2017-12-21 Moleculas de union para el tratamiento del cancer. MX2019007511A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437770P 2016-12-22 2016-12-22
EP17155973.5A EP3360898A1 (en) 2017-02-14 2017-02-14 Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
PCT/EP2017/084002 WO2018115231A2 (en) 2016-12-22 2017-12-21 Binding molecules for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2019007511A true MX2019007511A (es) 2019-09-04

Family

ID=58043942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007511A MX2019007511A (es) 2016-12-22 2017-12-21 Moleculas de union para el tratamiento del cancer.

Country Status (15)

Country Link
US (2) US10858438B2 (es)
EP (2) EP3360898A1 (es)
JP (1) JP7196076B2 (es)
KR (1) KR102651761B1 (es)
CN (1) CN110582513B (es)
AU (1) AU2017384687A1 (es)
BR (1) BR112019011750A2 (es)
CA (1) CA3046591A1 (es)
CO (1) CO2019006320A2 (es)
EA (1) EA201991480A1 (es)
MA (1) MA47121A (es)
MX (1) MX2019007511A (es)
PE (1) PE20191251A1 (es)
TW (1) TWI790219B (es)
WO (1) WO2018115231A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3725370A1 (en) * 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CA3180665A1 (en) * 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
KR20230133331A (ko) 2021-01-15 2023-09-19 씨젠 인크. 면역조절 항체-약물 컨쥬게이트
CN116847886A (zh) 2021-02-03 2023-10-03 思进公司 免疫刺激化合物及缀合物
KR20240017937A (ko) * 2021-06-07 2024-02-08 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 치료제의 표적화된 전달을 위한 조성물 및 방법
CN113512117B (zh) * 2021-07-12 2023-08-22 武汉麦考津生物科技有限公司 一种可结合cd206的抗体及其应用
WO2023015169A1 (en) * 2021-08-02 2023-02-09 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
EP4388013A1 (en) * 2021-08-20 2024-06-26 University of Virginia Patent Foundation Strategy for highly superior dr5 activation including in tumors and cancers
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
US20240052065A1 (en) 2022-07-15 2024-02-15 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
WO2024081930A1 (en) * 2022-10-14 2024-04-18 Flagship Pioneering Innovations Vii, Llc Compositions and methods for targeted delivery of therapeutic agents
CN115785269B (zh) * 2022-11-01 2023-09-22 四川大学 抗pd-l1的抗体及其应用
WO2024102962A1 (en) 2022-11-10 2024-05-16 Immuvia Inc Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731A (en) 1848-08-22 Elisha k
US168A (en) 1837-04-17 Improvement in fire-arms
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JP3444885B2 (ja) 1992-08-21 2003-09-08 フリーイェ・ユニヴェルシテイト・ブリュッセル Ｌ鎖欠落免疫グロブリン
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
WO1994029347A1 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
WO1998048837A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP2067488A1 (en) 2000-04-12 2009-06-10 Human Genome Sciences, Inc. Albumin fusion proteins
EP2706116A1 (en) 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
NZ532881A (en) 2001-12-20 2008-04-30 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
MXPA05004955A (es) 2002-11-08 2005-11-17 Ablynx Nv Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos.
ES2315664T3 (es) 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060228352A1 (en) 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
SG10201400973XA (en) 2005-10-12 2014-08-28 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
US9181339B2 (en) * 2009-04-20 2015-11-10 Oxford Bio Therapeutics Ltd. Antibodies specific to cadherin-17
MX2012003598A (es) * 2009-09-29 2012-04-20 Roche Glycart Ag Anticuerpos biespecificos agonistas de receptores de muerte.
CA2815041A1 (en) 2010-10-20 2012-04-26 Oxford Biotherapeutics Ltd. Antibodies
US20130025987A1 (en) 2011-07-18 2013-01-31 David Batterbee Methods and apparatus for controlling a fluid damper
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
NO2776305T3 (es) 2014-04-23 2018-01-27
MX2017001946A (es) 2014-08-12 2017-06-19 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6.
MX2017006301A (es) 2014-11-14 2017-08-21 Novartis Ag Conjugados de anticuerpo- farmaco.
NZ732922A (en) 2015-01-20 2022-07-29 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
EP3250601A4 (en) 2015-01-26 2018-07-11 MacroGenics, Inc. Multivalent molecules comprising dr5-binding domains
JP6585860B2 (ja) 2016-05-18 2019-10-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんの処置のための抗ｐｄ１抗体及び抗ｌａｇ３抗体
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer

Also Published As

Publication number Publication date
JP2020501586A (ja) 2020-01-23
US11851495B2 (en) 2023-12-26
KR102651761B1 (ko) 2024-03-26
US10858438B2 (en) 2020-12-08
TW201835102A (zh) 2018-10-01
KR20190099223A (ko) 2019-08-26
US20180179287A1 (en) 2018-06-28
EP3360898A1 (en) 2018-08-15
EA201991480A1 (ru) 2020-01-15
MA47121A (fr) 2019-10-30
AU2017384687A1 (en) 2019-06-13
CA3046591A1 (en) 2018-06-28
WO2018115231A2 (en) 2018-06-28
EP3559040A2 (en) 2019-10-30
US20210095038A1 (en) 2021-04-01
TWI790219B (zh) 2023-01-21
CN110582513B (zh) 2023-11-14
WO2018115231A3 (en) 2018-08-02
JP7196076B2 (ja) 2022-12-26
PE20191251A1 (es) 2019-09-18
BR112019011750A2 (pt) 2019-10-29
CO2019006320A2 (es) 2019-06-28
CN110582513A (zh) 2019-12-17

Similar Documents

Publication Publication Date Title
MX2019007511A (es) Moleculas de union para el tratamiento del cancer.
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
PH12017500802B1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
MX2017006610A (es) Terapia combinada de moleculas de union a antigeno biespecificas activadoras de celulas t y antagonistas de union de eje de pd-1.
TW201613901A (en) New compounds
PH12015500825A1 (en) Substituted benzene compounds
PH12016502249A1 (en) Pladienolide pyridine compounds and methods of use
PH12016502607A1 (en) Functionalised and substituted indoles as anti-cancer agents
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MD20160130A2 (ro) Anticorpi umanizaţi contra CEACAM1
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX2016013029A (es) Compuestos de indanona sustituidos como modulares de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
MY184878A (en) Compositions and methods for treating neurodegenerative diseases
PH12016501393B1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
MX2017009608A (es) Compuestos anticancerigenos.
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
WO2016087932A3 (en) Macromolecular transition metal complexes for treatment of cancer and process for their preparation
PH12019501386A1 (en) Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
MX2017008475A (es) Novedoso anticuerpo humanizado adam17.
MY182809A (en) Compositions for the treatment of kidney and/or liver disease